New trends in the treatment of scleroderma renal crisis

Nephron

Volumn 92, Issue 3, 2002, Pages 716-718

  Shor, R ^a   Halabe, Aaron ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Renal crisis; Scleroderma; Statins

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DRUG MECHANISM; EDEMA; GLOMERULUS; KIDNEY DISEASE; KIDNEY INJURY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; SCLERODERMA;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; NEPHROLOGY; PROTEIN ISOPRENYLATION; SCLERODERMA, SYSTEMIC;

EID: 0036423327     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064073     Document Type: Article

References (27)

1. Fisher ER, Rodnan GP: Pathologic observations concerning renal involvement in progressive systemic sclerosis (PSS). Arch Pathol Lab Med 1958;65:29-39.
2. Steen V: Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22(4):861-878.
3. Cannon PJ, Hassar M, Case DB, et al: The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974;53:1-46.
4. Fleischmajer R, Gould AB: Serum renin and renin substrate levels in scleroderma. Proc Soc Exp Biol Med 1975;150:374-379.
5. Nussbaum AI, LeRoy EC: Renal involvement in scleroderma (systemic sclerosis); in Bacon PA, Hadler NM (eds): The Kidney and Rheumatic Disease. London, Butterworth Scientific, 1986, pp 282-296.
6. Steem VD, Medsger TA, Osial TA, et al: Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-786.
7. Clements PJ, Lachengruch PA, Furst DE, et al: Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year follow-up. Arthritis Rheum 1994;37:67-74.
8. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335: 1001-1009.
9. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622.
10. Faggiotto A, Paoletti R: Statin and blockers of the renin-angiotensin system. Hypertension 1999;34:987-996.
11. Khwaja A, Connolly JO, Hendry BM: Prenylation inhibitors in renal disease. Lancet 2000; 355:741-744.
12. Essing M, Nguyen G, Prie D, Escoubet B, Staer JD, Friedlander G: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranyl geranylation and Rho protein. Circ Res 1998;83:683-690.
13. Corsini A, Bernini F, Quarato P, et al: Nonlipid-related effects of 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996;87:458-468.
14. Tayeh MA, Scicli AG: Angiotensin II and bradykinin regulate the expression of P-selection on the surface of endothelial cells in culture. Proc Assoc Am Phys 1998;110:412-421.
15. Guijarro C, Blanco-Colio LM, Ortego M, et al: 3-Hydroxy-3-methylglutaryl coenzyme A reductase and usoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
16. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB: Lovastatin induces fibroblast apoptosis in vitro and in vivo: A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999;159:220-227.
17. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974.
18. Mitani H, Bandon T, Ishikawa J, Kimura M, Totsuka T, Hayashi S: Inhibitory effects of fluvastatin, a new HMG-CoA reduces inhibitor, on the increase in vascular ACE activity in cholesterolfed rabbits. Br J Pharmacol 1996;119: 1269-1275.
19. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97;1129-1135.
20. Brandes RP, Behra A, Lebherz C, Boger RH, Bode-Boger SM, Mugge A: Lovastatin maintains nitric oxide, but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Atherosclerosis 1999;142:97-104.
21. Endres M, Laufs U, Huang Z, et al: Stroke protection by of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885.
22. Bellosta S, Bernini F, Ferri N, et al: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137:S101-S109.
23. Park JK, Muller DN, Mervaala EM, et al: Cerivastatin prevents II-induced renal injury independent of blood pressure and cholesterol-lowering effects. Kidney Int 2000;58(4):1420-1430.
24. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974.
25. Bos JL: The ras gene family and human carcinogenesis. Muter Res 1998;195:255-271.
26. Glorioso N, Troffa C, Filigheddu F, et al: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1286.
27. Nazzaro P, Manzari M, Merlo M, Triggiani R, et al: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-725.